Evidence map›Paper›PMID 30245507›Full record

ArticleGenes and immunity2019

Polymorphism of FCGR3A gene in chronic beryllium disease.

Bing Liu, Lisa A Maier, Nabeel Hamzeh, Kristyn MacPhail, Margaret M Mroz, Hongbo Liu, Li Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bing LiuDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Lisa A MaierDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Nabeel HamzehDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Kristyn MacPhailDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Margaret M MrozDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Hongbo LiuDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA.
Li LiDivision of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, CO, USA. lil@njhealth.org.
University of Colorado Denver · USNational Jewish Health · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
T Cells in Beryllium Sensitization and DiseaseP01ES011810 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI FONTENOT, ANDREW P. · 2002 to 2013
$14.0M
Exposure in Epigenetic Regulation of Immune Response in CBDR01ES023826 · NIEHS · NATIONAL JEWISH HEALTH · PI MAIER, LISA A, YANG, IVANA V · 2015 to 2019
$2.3M
The immunoregulatory role of Alveolar Macrophages in Chronic Beryllium DiseaseR01ES025722 · NIEHS · NATIONAL JEWISH HEALTH · PI LI, LI · 2016 to 2020
$1.8M
Functional Genomics Approach to the Role of the JAK/STAT and MAPK Pathway in CBDK01ES020857 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI LI, LI · 2011 to 2013
$382k
National Center for Advancing Translational Sciences UL1 TR001082National Institute of Environmental Health Sciences K01 ES020857National Institute of Environmental Health Sciences P01 ES011810National Institute of Environmental Health Sciences R01 ES023826National Institute of Environmental Health Sciences R01 ES025722NIEHS NIH HHS K01 ES020857NIEHS NIH HHS P01 ES011810NIEHS NIH HHS R01 ES023826NIEHS NIH HHS R01 ES025722
6 · The paper itself

Abstract

Previously we showed that alveolar macrophages (AMs) from patients with chronic beryllium disease (CBD) and beryllium sensitization (BeS) demonstrated significantly greater cell surface CD16 (encoded by the FCGR3A gene) than controls. We hypothesized that these differences were related to polymorphisms in the FCGR3A gene. This study was to determine the association between FCGR3A polymorphisms in CBD, BeS versus controls as well as clinical data, providing potential information about disease pathogenesis, risk, and activity. A total of 189 CBD/154 BeS/150 controls (92 Be-exposed non-diseased and 58 healthy controls) were included in this study. Sequence-specific primers polymerase chain reaction (PCR-SSP) was used to determine FCGR3A 158V/F polymorphisms. We found significantly higher frequencies of the 158V allele (OR: 1.60 (CI: 1.17-2.19), p = 0.004) and 158VV homozygotes (OR: 2.97 (CI: 1.48-5.97) p = 0.007) in CBD versus controls. No differences were found in the frequencies of FCGR3A alleles or genotypes between BeS versus controls and CBD versus BeS. Average changes in exercise testing maximum workload (Wlm), maximum oxygen consumption (VO

Indexed as

AdultAgedAllelesBerylliosisBerylliumChronic DiseaseFemaleGenotypeHumansLungMaleMiddle AgedPolymorphism, GeneticReceptors, IgGRisk FactorsBerylliumFCGR3A protein, humanReceptors, IgG

Identifiers

PMID30245507
PMCPMC6431584
OpenAlexW2891830224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.